Horizon Discovery Group Signs Agreement With Top 10 Pharma Company

Horizon Discovery Group plc recently announced that its Horizon CombinatoRx division has been contracted by a top 10 pharma company to profile a lead oncology asset. Under the terms of the agreement, Horizon CombinatoRx will be paid approximately $450,000 (GBP £276,000) for work to be completed within a 6-month period.

Horizon will provide services to support proof-of-concept, monotherapy screening, and combination screening for the lead asset. Horizon CombinatoRx provides its partners access to the unique cHTS platform and Chalice analytics software, which enables the screening and analysis of thousands of complementary drug combinations. Combined with Horizon’s GENESIS (rAAV, CRISPR, and ZFN) gene-editing platform and X-MAN isogenic cell line technology, Horizon CombinatoRx offers services, including novel phenotypic cell-based screens with compound siRNA, shRNA, and sgRNA (for CRISPR-based screening) libraries.

Dr. Darrin M. Disley, Chief Executive Officer of Horizon Discovery Group plc, said “We are delighted that Horizon CombinatoRx continues to gain traction in the market, following the acquisition earlier this year. This latest contract with a top 10 pharma in the oncology space continues to demonstrate the potential of this business and the value Horizon CombinatoRx can offer to support key drug discovery and development programs in cancer.”

Horizon Discovery completed the acquisition of the CombinatoRx service business and assets from Zalicus Inc. in June 2014. Horizon is a revenue-generating life science company supplying research tools to organizations engaged in genomics research and the development of personalized medicines. Horizon has a diverse and international customer base approaching 1,000 organizations across nearly 50 countries, including major pharmaceutical, biotechnology and diagnostic companies as well as leading academic research centers. The company supplies its products and services into multiple markets, estimated to total in excess of £29 billion by 2015.

Horizon’s core capabilities are built around its proprietary translational genomics platform, GENESIS, a high-precision and flexible suite of gene-editing tools able to alter almost any endogenous gene sequence of human or mammalian cell-lines. Horizon offers almost 2,200 products, almost all of which are based on the application of GENESIS to generate cell lines that accurately model the disease-causing mutations found in genetically based diseases. These “patients-in-a-test-tube” are being used by customers to identify the effect of individual or compound genetic mutations on drug activity, patient responsiveness, and resistance, which may lead to the successful prediction of which patient sub-groups will respond to currently available and future drug treatments.

In addition, Horizon provides GENASSIST CRISPR and rAAV gene-editing tools, custom cell line generation services for research and bioproduction applications, quantitative molecular reference standards, in vivo disease models, contract research and custom screening services, custom shRNA development services, and off-the-shelf validated shRNA (through Horizon’s partner Sirion), and haploid cell lines (through Horizon’s partner Haplogen). These latter partnerships provide Horizon with almost 11,000 further products for our customers.

Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange’s AIM market under the ticker HZD. For more information, visit www.horizondiscovery.com.